Xeris Pharmaceuticals
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Xeris Pharmaceuticals (XERS) | 3.10B | -628.52 | 63.56 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 21.8% above Morningstar's fair value estimate.
Fair value
Xeris Biopharma Holdings Inc receives a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 26% premium over our quantitative fair value estimate of $13.26 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 1.8%, which sits in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.0%, a core component of profitability, lies in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.
Xeris Pharmaceuticals discussion 0 comments